These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 27039131)

  • 1. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
    Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
    JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
    Ter Maaten JM; Valente MA; Damman K; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Bloomfield DM; Cotter G; Davison B; Subacius H; van Veldhuisen DJ; van der Meer P; Hillege HL; Gheorghiade M; Voors AA
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27266853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.
    DeVore AD; Hasselblad V; Mentz RJ; O'Connor CM; Armstrong PW; McMurray JJ; Ezekowitz JA; Tang WH; Starling RC; Voors AA; Califf RM; Hernandez AF
    Eur J Heart Fail; 2015 Mar; 17(3):340-6. PubMed ID: 25619549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
    Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M;
    Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
    Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial.
    Sarma S; Mentz RJ; Kwasny MJ; Fought AJ; Huffman M; Subacius H; Nodari S; Konstam M; Swedberg K; Maggioni AP; Zannad F; Bonow RO; Gheorghiade M;
    Eur J Heart Fail; 2013 Feb; 15(2):194-202. PubMed ID: 23059198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
    Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
    J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial.
    Dunlay SM; Gheorghiade M; Reid KJ; Allen LA; Chan PS; Hauptman PJ; Zannad F; Maggioni AP; Swedberg K; Konstam MA; Spertus JA
    Eur J Heart Fail; 2010 Apr; 12(4):367-74. PubMed ID: 20197265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).
    Lala A; McNulty SE; Mentz RJ; Dunlay SM; Vader JM; AbouEzzeddine OF; DeVore AD; Khazanie P; Redfield MM; Goldsmith SR; Bart BA; Anstrom KJ; Felker GM; Hernandez AF; Stevenson LW
    Circ Heart Fail; 2015 Jul; 8(4):741-8. PubMed ID: 26041600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
    JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion.
    Faselis C; Lam PH; Patel S; Arundel C; Filippatos G; Deedwania P; Zile MR; Wopperer S; Nguyen T; Allman RM; Fonarow GC; Ahmed A
    Am J Med; 2021 Jun; 134(6):797-804. PubMed ID: 33359271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loop diuretic down-titration at discharge in patients hospitalized for acute heart failure.
    Croset F; Llàcer P; Núñez J; Campos J; García M; Pérez A; Fernández C; Fabregate M; López G; Tello S; Fernández JM; Ruiz R; Manzano L
    ESC Heart Fail; 2024 Jun; 11(3):1739-1747. PubMed ID: 38454739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
    Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
    Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.